Skip to main content
. 2015 Jun;100(6):786–793. doi: 10.3324/haematol.2014.123273

Figure 4.

Figure 4.

CNS relapse incidence and outcome estimates with 95% confidence intervals (CI) by randomization arm. (A) Three-year CNS relapse incidence: ITT (n=66), four CNS relapses (6.1%, 95% CI 2–14%), two isolated (3%, 95% CI 0.6–9%) and two combined (3.1%, 95% CI 0.6–9%); ITD (n=64), two isolated CNS relapses (3.1%, 95% CI 0.8–14%) (P=0.43). (B) Overall survival: ITT (n=74), median duration 4.5 years, 62% at 3 years (95% CI 49–74%) and 58% at 4 years (95% CI 44–72%); ITD (n=71), median duration 4.0 years, 53% at 3 and 4 years (95% CI 40–66%) (P=0.44). (C) Disease-free survival: ITT (n=66), median duration not reached, 54% at 3 and 4 years (95% CI 40–67%); ITD (n=64), median duration 3.9 years, 53% at 3 years (95% CI 39–66%) and 48% at 4 years (95% CI 34–63%) (P=0.54).